Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q8IWY9
UPID:
CDAN1_HUMAN
Alternative names:
-
Alternative UPACC:
Q8IWY9; Q6NYD0; Q7Z7L5; Q969N3
Background:
Codanin-1, encoded by the gene with accession number Q8IWY9, plays a crucial role in cellular processes by acting as a negative regulator of ASF1 in chromatin assembly. This regulation is vital for maintaining the integrity of genetic information during cell division and differentiation. The protein's unique structure, characterized by its ability to interact with various components of the chromatin assembly pathway, positions Codanin-1 as a key player in cellular homeostasis.
Therapeutic significance:
The association of Codanin-1 with congenital dyserythropoietic anemia, type 1A, underscores its clinical importance. This autosomal recessive blood disorder highlights the protein's pivotal role in erythropoiesis and iron metabolism. Understanding the role of Codanin-1 could open doors to potential therapeutic strategies aimed at correcting the underlying genetic defects, thereby offering hope for patients suffering from this and potentially related disorders.